drugset
drugset / Trial / NCT00144976

Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

NCT00144976 ↗

Completed 43 enrolled Institut Claudius Regaud Roche Pharma AG · collab
Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to evaluate the biological effect of Tarceva (OSI-774) from an inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who are carriers of head and neck epidermoid carcinoma.

Timeline

Start
2003-10
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule 150 mg —

Indications

head and neck neoplasm